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ackground: Vitamin D is hypothesized to have some roles in innate and adaptive immunity, inﬂammation
eduction, and remodeling; therefore, it is supposed to affect the asthma phenotype, severity, and response
inhaled corticosteroid (ICS).
bjective: To explore the synergistic effects of vitamin D supplementation in addition to asthma controllers
(ICS or ICS plus long-acting b-agonist) on airway functions.
Methods: A randomized clinical trial was conducted in 130 individuals aged 10 to 50 years who lived in
Tehran during a 24-week period. Data on age, sex, body mass index, stage of asthma, serum total IgE, history
of allergic rhinitis, atopic dermatitis, food allergy, and urticaria were collected. Spirometric parameters
(forced expiratory volume in 1 second [FEV1] and ratio of FEV1 to forced vital capacity) and serum vitamin D
measurement were obtained before and 8 and 24 weeks after the intervention. Patients were divided in 2
groups randomly. Both groups received asthma controllers (budesonide or budesonide plus formoterol)
according to their stage, but the intervention group received vitamin D supplementation (100,000-U bolus
intramuscularly plus 50,000 U orally weekly) in addition to asthma controllers.
Results: FEV1 improved signiﬁcantly in both groups after 8 weeks, but no signiﬁcant difference was found
between the 2 groups at baseline (P ¼ .20) or after 8 weeks (P ¼ .99); however, a signiﬁcant improvement
was seen in the intervention group in the last 16 weeks, and FEV1 was signiﬁcantly better in the intervention
group than the other group after 24 weeks (P < .001).
Conclusion: Vitamin D supplementation associated with asthma controllers could signiﬁcantly improve
FEV1 in mild to moderate persistent asthma after 24 weeks.
Trial Registration: irct.ir Identiﬁer: IRCT201302079608N1.
 2014 American College of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.Introduction supplementation with the active pharmacologic form of vitamin DThere are no clear reasons for the increased prevalence of allergic
diseases, especially asthma, in recent decades.1,2 Some epidemio-
logic studies suggest that vitamin D deﬁciency is associated with an
increased incidence of asthma symptoms.3,4 Vitamin D has a critical
role in corticosteroid resistance in asthma, suggesting that vitamin D
may play a role in the control of asthma.5 Some studies suggest that
vitamin D interacts with glucocorticoid signaling pathways5 andAllergy, Rasool e Akram Hospital,
n; E-mail: fallahpour.morteza@
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enhances dexamethasone-induced expression of interleukin (IL) 10
by T-regulatory cells.6 It has been already reported that vitamin D
has several effects on the innate and adaptive immune system that
might be relevant to asthma morbidity.7e10 A number of studies
have concluded that low 25-hydroxy-vitamin D in mild to moderate
asthma is correlated with poor asthma control, reduced lung func-
tion, reduced glucocorticoid response, more frequent exacerbations,
and increased corticosteroid use.10e12 Even though there are sufﬁ-
cient basic and epidemiologic studies to support a causal relation-
ship between vitamin D and asthma, clinical data that address the
effect of vitamin D supplementation on disease control and severity
are limited in asthma patients. Therefore, the aim of this clinical triallsevier Inc. All rights reserved.
al Sciences from ClinicalKey.com by Elsevier on May 20, 2019.
 Copyright ©2019. Elsevier Inc. All rights reserved.
S. Arshi et al. / Ann Allergy Asthma Immunol 113 (2014) 404e409 405was to investigate the synergistic role of vitamin D supplementation
on airway functions in addition to standard asthma treatment.
Methods
This prospective, randomized, open-label, active controlled
clinical trial was designed in an outpatient setting, and patients
with mild to moderate persistent asthma 10 to 50 years old
were enrolled according to inclusion and exclusion criteria.
Rasool-e-Akram is a referral hospital in Tehran, and the study
participants were selected from patients visited in the allergy or
pulmonology clinics of the hospital. Because some interventional
factors, such as skin pigmentation, diet, sun exposure level, and
clothing habits, can affect vitamin D metabolism, only native Fars
patients living in Tehranwere selected, so our patients hadminimal
difference in skin color.
However, we did not check their dietary intake of vitamin D. The
main inclusion criteria were a diagnosis of mild to moderate persis-
tent asthma according to the Global Initiative for Asthma 2012,13 age
of 10 to 50 years, and consent to participate in this study. Exclusion
criteria were a diagnosis of chronic obstructive pulmonary disease,14
known sarcoidosis, hyperparathyroidism, nephrolithiasis, active
tuberculosis, vitamin D intolerance, liver failure, renal failure, lym-
phoma or other malignant tumors not in remission for more than 2
years,15,16 treatment with anticonvulsants, vitamin D supplementa-
tion, systemic corticosteroid therapy up to 3months before or during
the study,17 breastfeeding or pregnancy, baseline serum calcium level
greater than 2.65 mmol/L, asthma exacerbation 3 months before or
during the study, active or passive smoking, and incomplete use of
asthma controller drugs during the study. One hundred sixty in-
dividualswere selectedduring routine visits in our clinic based on the
outlined criteria, but only 130 patients participated once they were
notiﬁedofbeginning thestudy (64 in the interventiongroupand66 in
the control group) and 30 patients did not participate in the study at
the timeofnotiﬁcation.Allparticipantswerenotiﬁedat thesametime
in April 2013. Using consecutive random selection, the participants
were divided in 2 groups of intervention and control. Spirometry and
serum25-hydroxy-vitaminD levelwasmeasuredbefore and8and24
weeks after the study. Spirometrywas performed in accordancewithFigure 1. Algorithm
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Rasool-e-Akram Hospital using JAEGER (Jaeger, Master Screening
PAED,Hoechburg,Germany) and thebest forcedexpiratory volume in
1 second (FEV1) and forced vital capacity (FVC) were recorded.
The serum level of 25-hydroxy-vitamin D was measured by
radioimmunoassay19 using 25-hydroxy-vitamin D enzyme immu-
noassay (AC-57F1.ids.UK). Spirometry, vitaminDmeasurement, and
determination of level of asthma controlwere performed at 0, 8, and
24 weeks. Fifteen patients were lost to follow-up during the ﬁrst 8
weeks (6 patients in the intervention group and 9 in the control
group), and 7 patients were lost to follow-up during the next 16
weeks (3 in the intervention group and 4 in the control group).
During theﬁrst 8weeks, 7 patientswereexcludedbecauseof asthma
exacerbation (4 in the intervention group and 3 in the control
group), 6patientswere excludedbecauseof pooradherence (2 in the
intervention group and 4 in the control group), and 2 patients were
excluded because of stepping up to the severe persistent level. In the
next 16 weeks, 7 patients were lost to follow-up (3 in the inter-
vention group and 4 in the control group), which was due to poor
adherence without changing the level of asthma treatment; there-
fore, a total of 108patients completed the study (Fig 1). Adherence to
vitamin D and asthma controller drug was evaluated on the basis of
weekly follow-up through telephone calls. Budesonide alone or
budesonide plus formoterol both in the form of dry powder inhaler
were prescribed after adjustment according the stage of asthma.
Patients in the intervention group received abolusdoseof 100,000U
of vitamin D intramuscularly followed by 50,000 U of oral vitamin D
pearls on a weekly basis.20e22 No serious adverse reactions or
adverse effects were noticed during vitamin D supplementation.
The study was approved by the Ethics Committee and was
registered at www.irct.ir (Identiﬁer IRCT201302079608N1). The
patients were informed about the aim of the study and were
instructed on how to use a dry powder inhaler. Moreover, an
informed consent form was consequently signed by each partici-
pant. Efﬁcacy was assessed using intent-to-treat analyses. Numeric
and categorical variables were described with mean (SD) and
relative frequency, respectively. We used paired-samples t tests and
independent-samples t tests to compare mean numeric variablesof the study.
al Sciences from ClinicalKey.com by Elsevier on May 20, 2019.
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Table 1
Characteristics of the study participants before the study
Characteristic Intervention group (n ¼ 64) Control group (n ¼ 66) P value
Age, mean (range), y 24.40 (10.5e49.0) 28.64 (10.0e49.1) .25
BMI 23.04 (16.5e35.5) 24.09 (15.64e38.0) .88
Female, % 57.8 63.6 .49
Male, % 42.2 36.4
Mild persistent asthma, No. (%) 33 (51.6) 39 (59.1) .87
Moderate persistent asthma, No. (%) 31 (48.4) 27 (40.9)
IgE level, IU/mL 133.15 (11e409) 120.19 (8e492) .32
Allergic rhinitis, No. (%) 37 (57.8) 38 (57.6) .95
Atopic dermatitis, No. (%) 16 (25.0) 14 (21.2) .31
Urticaria, No. (%) 9 (14.3) 10 (15.4) .72
Food allergy, No. (%) 12 (18.8) 6 (9.2) .82
Vitamin D level before study, ng/mL 23.82 (5.4e70.7) 24.02 (5.4e71.2) .93
Abbreviation: BMI, body mass index.
S. Arshi et al. / Ann Allergy Asthma Immunol 113 (2014) 404e409406within and across groups, respectively. The c2 test was used to
compare relative frequency between groups. The level of signiﬁcant
was considered .05. All analyses were performed with SPSS statis-
tical software, version 16 (SPSS Inc, Chicago, Illinois).Results
A total of 130 patients who met the inclusion criteria were
enrolled in this study and were randomly assigned to interventionFigure 2. A, Forced expiratory volume in 1 second (FEV1) before study (P¼ .16). B, FEV1 aft
capacity (FVC) before study (P ¼ .94). E, FEV1/FVC ratio after 8 weeks (P ¼ .73). F, FEV1/F
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asthma (mild persistent or moderate persistent), history of atopic
dermatitis, allergic rhinitis, food allergy or urticaria, serum total
IgE, FEV1, ratio of FEV1 to forced vital capacity (FVC), and serum
vitamin D were considered as variables for ﬁnal analysis. Of 130
enrolled patients, 72 cases (55.4%) had mild persistent asthma,
and 58 cases (44.6%) had moderate persistent asthma. The
mean (SD) vitamin D level was 23.5 (18.4) ng/mL in patients with
mild persistent asthma and 24.4 (17.5) ng/mL in patients wither 8 weeks (P¼ .99). C, FEV1 after 24weeks (*P< .001). D, Ratio of FEV1 to forced vital
VC ratio after 24 weeks (P ¼ .06). *P < .05 indicate statistical signiﬁcance.
al Sciences from ClinicalKey.com by Elsevier on May 20, 2019.
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(P ¼ .77). Demographic data of the patients are presented in
Table 1. No signiﬁcant differences were observed between 2
groups before the study. FEV1 had a signiﬁcant improvement after
8 weeks in both groups (P < .001 in the intervention group and
P ¼ .001 in the control group), but there was no signiﬁcant dif-
ference between the 2 groups at the 8-week analysis (P ¼ .16)
(Fig 2). During the next 16 weeks, between 8 and 24 weeks, the
FEV1 signiﬁcantly improved only in the intervention group with
no signiﬁcant change in the control group (P < .001 in the inter-
vention group and P ¼ .64 in control group). In ﬁnal analysis at
week 24, the FEV1 was signiﬁcantly higher in the intervention
group (P < .001) (Fig 2). The FEV1/FVC ratio had a signiﬁcant
improvement after 8 and 24 weeks in the intervention group
(P ¼ .002 after 8 weeks and P < .001 after 24 weeks), whereas the
improvement was signiﬁcant only after 24 weeks in the control
group (P ¼ .48 after 8 weeks and P ¼ .001 after 24 weeks). The
FEV1/FVC ratio did not reveal a signiﬁcant difference between the
2 groups at 8 and 24 weeks (P ¼ .73 after 8 weeks and P ¼ .06 after
24 weeks) (Fig 2). There was a positive correlation between
serum vitamin D and FEV1 before the study in all patients
(P ¼ .001, r ¼ 0.272); however, after 8 weeks of treatment, this
rhythm had a negative correlation between vitamin D and FEV1
without any signiﬁcant difference (P ¼ .25, r ¼ 0.063), but after
24 weeks there was again a positive correlation between serum
vitamin D level and FEV1 with a signiﬁcant difference (P < .001,
r ¼ 0.336). The correlation between D vitamin D and D FEV1
was also measured after 8 (r ¼ 0.092, P ¼ .33) and 24 (r ¼ 0.543,
P < .001) weeks (Fig 3, C and D). FEV1 and vitamin D level changes
during the study are shown in Figure 3, A and B, for each group.Figure 3. A, Vitamin D changes during study in each group. B, Forced expiratory volume i
FEV1 with D vitamin D after 8 weeks (r ¼ 0.092, P ¼ .33). D, Correlation between D FEV
signiﬁcance.
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Long-term inhaled corticosteroids are the main asthma con-
trollers; however, a substantial proportion of patients do not ach-
ieve optimal asthma control despite high-dose treatment.23 In
addition, many of the patients are prone to recurrent exacerbations
because of common respiratory viral infections.2 Vitamin D is
required for fetal lung development.24 It interacts with glucocor-
ticoid signaling pathways.5 Investigations have found that vitamin
D3 can induce expression of interleukin 10 by T-regulatory cells6
and block smooth muscle proliferation in a concentration-
dependent manner in human smooth muscle, both of which are
outlined in asthma pathogenesis.25 Furthermore, vitamin D has
multiple cytokine modulatory effects.26,27 Vitamin D increases the
production of cathelicidine in macrophages and has a beneﬁcial
effect on the clearance of infections.28e31
Recent publications indicate that maternal intake of vitamin D
during pregnancy leads to a decreased risk of recurrent wheezing
in young children.32,33 There are already many basic and epide-
miologic surveys indicating the effect of vitamin D in asthma, but
there are not enough trials. Yadav et al34 found that 60,000 U of
vitamin D monthly for 6 months, in addition to treating asthma,
could reduce the asthma severity, number of exacerbations,
corticosteroid use, emergency department visits, and peak expi-
ratory ﬂow rate.34 Clifford and Knox35 outlined different roles
and mechanisms through which vitamin D may affect asthma,
including variable adaptive and innate mechanisms. Despite the
increasing evidence supporting the beneﬁcial role of vitamin D in
asthma treatment, there are still some controversies; for
example, Ginde et al36 reported that vitamin D supplementationn 1 second (FEV1) changes during the study in each group. C, Correlation between D
1 with D vitamin D after 24 weeks (r ¼ .543, P < .001). *P < .05 indicate statistical
al Sciences from ClinicalKey.com by Elsevier on May 20, 2019.
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31 years; so, it is clear that more trials are needed to clarify any
potential role of vitamin D as a therapeutic option for asthma
treatment.
On the basis of these facts, the present study was designed to
deﬁne the therapeutic role of vitamin D as an adjunct to asthma
treatment. Varney et al37 reported successful treatment of a difﬁ-
cult case of airway dysfunction syndrome that was resistant to
inhaled corticosteroids with high-dose vitamin D. The patient’s
symptoms resolved at a vitamin D level of more than 150 nmol/L.37
Because different functions of vitamin D (eg, bone mineral meta-
bolism, immunologic, and secretory) appear in different serum
levels and are dose dependent and there are suggestions that levels
greater than 40 ng/mL are optimal for vitamin D immune func-
tions9,38,39 and considering the immunomodulatory aspects of
vitamin D, we used high-dose vitamin D (100,000-U bolus plus
50,000 U weekly for 24 weeks) in our study, which was in the
permitted range according to the literature.20e22 After 8 weeks, the
FEV1 improved in both groups, which has expected because both
groups used asthma controllers. There was no difference between
the 2 groups after 8 weeks (P ¼ .99). Vieth et al,40 Lange et al,41 and
Di Rosa et al42 explained the different immune modulatory aspects
of vitamin D in different cells; however, it obviously takes time
before they reach the appropriate concentration and exert their
effects. Therefore, we believe that 8 weeks is not enough for this
dose of vitamin D because vitamin D has its effects after 24 weeks.
On the basis of the correlation between vitamin D and FEV1, there
was a negative rhythm between serumvitamin D and FEV1 after the
ﬁrst 8 weeks of treatment (r ¼ 0.63, P ¼ .25), which we think can
be explained by the run-in period needed for developing vitamin D
immunologic effects; therefore, we believe that the improvement
in the ﬁrst 8 week in both groups was due to only asthma controller
treatments.
During the next 16 weeks, FEV1 did not improve signiﬁcantly in
the control group despite the regular use of asthma controllers,
whereas FEV1 improved signiﬁcantly by continuing use of the
controllers in the intervention group. In the end of study, there was
a signiﬁcant difference in FEV1 between the 2 groups (P< .001), and
interestingly there was a positive correlation between the vitamin
D level and FEV1 after 24 weeks with a signiﬁcant difference
(P < .001, r ¼ 0.366).
Because of the signiﬁcant difference in FEV1 between the 2
groups (P < .001) after 24 weeks and the positive correlation
(r¼ 0.336, P< .001) and the positive and signiﬁcant correlation of D
vitamin D and D FEV1 only after 24 weeks (r ¼ 0.543, P < .001), we
hypothesize that the signiﬁcant improvement in the 2 groups
resulted from vitamin D supplementation.
This article could be more strengthened by writing a symptom
score (Asthma Control Test or Asthma Control Questionnaire), but
unfortunately it was not done. In addition, the small sample size
(n ¼ 130) of the study and the high mean BMI of the participants
were the most important limitations of this study, although there
was no signiﬁcant difference in BMI between the both groups. We
did not use placebo for parallel control, which was another limi-
tation. We suggest further studies with larger sample sizes, stricter
inclusion and exclusion criteria (eg, BMI), and use of placebo and
different doses of vitamin D to determine the best effective dose of
vitamin D. In conclusion, according to our ﬁndings, vitamin D
supplementation may lead to a better and prolonged response to
asthma controllers. For this purpose, it is better to use vitamin D for
at least 24 weeks.References
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